BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 31777473)

  • 1. Prediction of Overall Survival and Progression-Free Survival by the
    Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R
    Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline
    Aide N; Fruchart C; Nganoa C; Gac AC; Lasnon C
    Eur Radiol; 2020 Aug; 30(8):4623-4632. PubMed ID: 32248365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumor Heterogeneity Assessed by
    Lue KH; Wu YF; Liu SH; Hsieh TC; Chuang KS; Lin HH; Chen YH
    Acad Radiol; 2020 Aug; 27(8):e183-e192. PubMed ID: 31761665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Parvez A; Tau N; Hussey D; Maganti M; Metser U
    Ann Nucl Med; 2018 Jul; 32(6):410-416. PubMed ID: 29754276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Metabolic Parameters and Textural Features in Pretreatment
    Wang G; Si Y; Liu J; Wang W; Yang J
    Acad Radiol; 2024 Mar; 31(3):1091-1101. PubMed ID: 37748956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic Value of
    Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Pretreatment Radiomic Features of 18F-FDG PET in Patients With Hodgkin Lymphoma.
    Lue KH; Wu YF; Liu SH; Hsieh TC; Chuang KS; Lin HH; Chen YH
    Clin Nucl Med; 2019 Oct; 44(10):e559-e565. PubMed ID: 31306204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of a Machine Learning Approach for the Analysis of Clinical and Radiomic Features of Pretreatment [
    Nakajo M; Jinguji M; Tani A; Kikuno H; Hirahara D; Togami S; Kobayashi H; Yoshiura T
    Mol Imaging Biol; 2021 Oct; 23(5):756-765. PubMed ID: 33763816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Functional Parameters of
    Wang M; Xu H; Xiao L; Song W; Zhu S; Ma X
    Contrast Media Mol Imaging; 2019; 2019():2641627. PubMed ID: 31427906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [
    de Jesus FM; Yin Y; Mantzorou-Kyriaki E; Kahle XU; de Haas RJ; Yakar D; Glaudemans AWJM; Noordzij W; Kwee TC; Nijland M
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1535-1543. PubMed ID: 34850248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL.
    Zhao P; Yu T; Pan Z
    Ann Nucl Med; 2021 Jan; 35(1):24-30. PubMed ID: 33001389
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
    J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional and novel [
    Leithner D; Flynn JR; Devlin SM; Mauguen A; Fei T; Zeng S; Zheng J; Imber BS; Hubbeling H; Mayerhoefer ME; Bedmutha A; Luttwak E; Corona M; Dahi PB; Luna de Abia A; Landego I; Lin RJ; Palomba ML; Scordo M; Park JH; Tomas AA; Salles G; Lafontaine D; Michaud L; Shah GL; Perales MA; Shouval R; Schöder H
    J Hematol Oncol; 2024 Apr; 17(1):21. PubMed ID: 38649972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
    Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
    Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.